Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Aarhus University Hospital, Exiqon deal

    Aarhus University Hospital, Aarhus, Denmark Exiqon A/S (CSE:EXQ), Vedbaek, Denmark Business: Diagnostic Exiqon received exclusive, worldwide rights to prostate cancer biomarkers comprising gene-specific methylation …

    Published on 12/15/2014
  • Accelerate Diagnostics, Centers for Disease Control and Prevention deal

    Accelerate Diagnostics Inc. (NASDAQ:AXDX), Tucson, Ariz. Centers for Disease Control and Prevention, Atlanta, Ga. Business: Diagnostic Accelerate partnered with the CDCs Rapid Antimicrobial Susceptibility Testing …

    Published on 12/15/2014
  • Advanced Biological Laboratories, Hong Kong Polytechnic University, University of Hong Kong deal

    Advanced Biological Laboratories S.A., Luxembourg, Luxembourg Hong Kong Polytechnic University, Hong Kong, China University of Hong Kong, Hong Kong, China Business: Infectious Advanced Biological and the universities …

    Published on 12/15/2014
  • arGEN-X, Shire deal

    arGEN-X N.V. (Euronext:ARGX), Breda, the Netherlands Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Business: Antibodies Shire exercised an option to advance one or more undisclosed human antibody product candidates …

    Published on 12/15/2014
  • Array BioPharma, Oncothyreon deal

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Business: Cancer Array granted Oncothyreon exclusive, worldwide rights to develop and commercialize ARRY-380 (ONT-380). …

    Published on 12/15/2014
  • Athera, Boehringer Ingelheim deal

    Athera Biotechnologies AB, Stockholm, Sweden Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cardiovascular Athera said Boehringer declined to exercise its exclusive, 2013 option to PC-mAb, a humanized mAb …

    Published on 12/15/2014
  • BioDuro, BioAtla deal

    BioDuro LLC, San Diego, Calif. BioAtla LLC, San Diego, Calif. Business: Antibodies BioAtla and BioDuro partnered to advance two undisclosed mAbs through preclinical and Phase I trials in China. The companies will out-…

    Published on 12/15/2014
  • Broad Institute, Sigma-Aldrich deal

    Broad Institute of MIT and Harvard, Cambridge, Mass. Sigma-Aldrich Corp. (NASDAQ:SIAL), St. Louis, Mo. Business: Genomics The Broad Institute granted Sigma-Aldrich non-exclusive, worldwide rights to develop and …

    Published on 12/15/2014
  • Clovis, GlaxoSmithKline deal

    Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Cancer Clovis and GlaxoSmithKline entered into a deal to conduct a Phase I/II clinical trial evaluating …

    Published on 12/15/2014
  • CorQuest Medical, Cardio3 BioSciences deal

    CorQuest Medical Inc., Miami, Fla. Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium Business: Cardiovascular Cardio3 acquired cardiovascular device company CorQuest for an undisclosed amount. …

    Published on 12/15/2014
  • Corticrine, Actinogen deal

    Corticrine Ltd., Edinburgh, U.K. Actinogen Ltd. (ASX:ACW), West Perth, Australia Business: Neurology Actinogen acquired Corticrine, a spinout of Edinburgh BioQuarter, the commercialization arm of the College of Medicine…

    Published on 12/15/2014
  • Cubist, Merck deal

    Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious Merck will acquire Cubist for $102 per share and $1.1 billion in assumption of debt …

    Published on 12/15/2014
  • Dana-Farber Cancer Institute, Astellas deal

    Dana-Farber Cancer Institute, Boston, Mass. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer Dana-Farber granted Astellas an option to license exclusive, worldwide rights to small molecule K-Ras (KRAS) …

    Published on 12/15/2014
  • Dynavax, GlaxoSmithKline deal

    Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Autoimmune, Musculoskeletal, Hepatic Dynavax regained worldwide rights to DV1179 following …

    Published on 12/15/2014
  • Gruenenthal, Forest Laboratories deal

    Gruenenthal Group, Aachen, Germany Forest Laboratories Inc., New York, N.Y. Business: Neurology Gruenenthal and Actavis plc (NYSE:ACT, Dublin, Ireland) terminated a 2010 deal granting Actavis subsidiary, Forest …

    Published on 12/15/2014
  • H. Lee Moffitt Cancer Center, Celgene deal

    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Moffitt granted Celgene exclusive, worldwide rights to develop and commercialize an undisclosed…

    Published on 12/15/2014
  • IntelGenx, Edgemont deal

    IntelGenx Corp. (TSX-V:IGX;OTCQX:IGXT), Saint-Laurent, Quebec Edgemont Pharmaceuticals LLC, Austin, Texas Business: Neurology Edgemont exercised an option under a 2012 deal with IntelGenx to extend a license for the …

    Published on 12/15/2014
  • Ipsen, Otonomy deal

    Ipsen Group (Euronext:IPN;Pink:IPSEY), Boulogne-Billancourt, France Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Business: Other Ipsen granted Otonomy exclusive, worldwide rights to data of gacyclidine in support of …

    Published on 12/15/2014
  • Isis Pharmaceuticals, Biogen Idec deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Business: Neurology Isis received a $10 million milestone payment from Biogen under a 2013 deal under which the …

    Published on 12/15/2014
  • Modern Biosciences, J&J deal

    Modern Biosciences plc, London, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune Modern Biosciences and Johnson & Johnsons Janssen Biotech Inc. subsidiary partnered to develop Modern …

    Published on 12/15/2014
  • New Paradigm Therapeutics, Alize Pharma deal

    New Paradigm Therapeutics Inc., Chapel Hill, N.C. Alize Pharma, Lyon, France Business: Musculoskeletal Alize received exclusive, worldwide rights from New Paradigm Therapeutics to develop and commercialize peptides …

    Published on 12/15/2014
  • Organovo Holdings, Yale School of Medicine deal

    Organovo Holdings Inc. (NYSE-M:ONVO), San Diego, Calif. Yale School of Medicine, New Haven, Conn. Business: Transplant The partners will develop 3D organ tissues for surgical transplantation research using Organovos …

    Published on 12/15/2014
  • Pharming, Santarus deal

    Pharming Group N.V. (Euronext:PHARM), Leiden, the Netherlands Santarus Inc., San Diego, Calif. Business: Cardiovascular Pharming received a $20 million milestone payment under a 2010 deal granting exclusive, North …

    Published on 12/15/2014
  • Potentia, Apellis deal

    Potentia Pharmaceuticals Inc., Louisville, Ky. Apellis Pharmaceuticals Inc., Crestwood, Ky. Business: Hematology, Ophthalmic Apellis is acquiring Potentia for an undisclosed sum. The deal includes IP, which will allow …

    Published on 12/15/2014
  • Regenicin, Amarantus BioScience deal

    Regenicin Inc. (OTCBB:RGIN), Little Falls, N.J. Amarantus BioScience Holdings Inc. (OTCQB:AMBS), San Francisco, Calif. Business: Dermatology Amarantus purchased IP related to Regenicins PermaDerm for $3.5 million in …

    Published on 12/15/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993